Deferred Tax Assets, Valuation Allowance in USD of Eiger BioPharmaceuticals, Inc. from Q4 2013 to Q4 2023

Taxonomy & unit: us-gaap: USD
Description: Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary: Eiger BioPharmaceuticals, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and change rate from Q4 2013 to Q4 2023.
Eiger BioPharmaceuticals, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2023 was $116,842,000, a 21% increase year-over-year.
Source SEC data: View on sec.gov

Deferred Tax Assets, Valuation Allowance, Quarterly (USD)

Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Eiger BioPharmaceuticals, Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period	Value	YoY Chg	Change %	Date	Report	Filed	Fiscal Year	Fiscal Period
Q4 2023	$116,842,000	+$20,424,000	+21%	31 Dec 2023	10-K	08 Apr 2024	2023	FY
Q4 2022	$96,418,000	+$25,127,000	+35%	31 Dec 2022	10-K	08 Apr 2024	2023	FY
Q4 2021	$71,291,000	+$10,544,000	+17%	31 Dec 2021	10-K	17 Mar 2023	2022	FY
Q4 2020	$60,747,000	+$6,954,000	+13%	31 Dec 2020	10-K	10 Mar 2022	2021	FY
Q4 2019	$53,793,000	+$7,558,000	+16%	31 Dec 2019	10-K	09 Mar 2021	2020	FY
Q4 2018	$46,235,000	+$13,633,000	+42%	31 Dec 2018	10-K	13 Mar 2020	2019	FY
Q4 2017	$32,602,000	+$3,415,000	+12%	31 Dec 2017	10-K	14 Mar 2019	2018	FY
Q4 2016	$29,187,000	+$17,269,000	+145%	31 Dec 2016	10-K	09 Mar 2018	2017	FY
Q4 2015	$11,918,000	+$5,614,000	+89%	31 Dec 2015	10-K	23 Mar 2017	2016	FY
Q4 2014	$6,304,000	-$21,270,000	-77%	31 Dec 2014	8-K/A	17 Jun 2016
Q4 2013	$27,574,000			31 Dec 2013	10-K	31 Mar 2015	2014	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.